CREBBP and chronic myelogenous leukemia, BCR-ABL1 positive: Our results show that the GATA1/MYC axis is as a key component of EP300/CREBBP bromodomain inhibitors mechanism of action in chronic myeloid leukemia (CML) cell line K562.